Ranbaxy Laboratories has signed an agreement to acquire product rights and manufacturing facility of Bangalore-based Biovel Lifesciences Pvt Ltd, for an undisclosed sum. Biovel's development pipeline comprises of vaccines and biotherapeutics.

 

This transaction with Biovel provides Ranbaxy an entry platform to manufacture vaccines as well as biotherapeutics. The vaccine and biotherapeutics business would be an important part of its growth strategy as highlighted by the Ranbaxy chief executive Atul Sobti.

crackcrack
Peers
Company Name CMP
Sun Pharma Inds. 1631.65
Dr. Reddys Lab 1235.15
Cipla 1314.85
Zydus Lifesciences 881.95
Lupin 2137.15
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×